Literature DB >> 20213386

Osteosarcoma multidisciplinary approach to the management from the pathologist's perspective.

A Kevin Raymond1, Norman Jaffe.   

Abstract

Osteosarcoma is a primary malignant tumor of the bone in which proliferating neoplastic cells produce osteoid and/or bone, if only in small amounts. This histological principle defines a tumor that usually affects young males more frequently than females, and disproportionately involves the long bones of the appendicular skeleton. These tumors are generally locally aggressive and tend to produce early, lethal systemic metastases. However, osteosarcoma is not a single disease but a family of neoplasms, sharing the single histological finding of osseous matrix production in association with malignant cells. The majority (i.e., 75%) of cases are relatively stereotypical from the demographic, clinical, radiographic and histologic points of view. These tumors generally occur in the metaphyseal portion of the medullary cavity of the long bone and are referred to as "Conventional Osteosarcoma." The group is sub classified by the form of the dominant matrix present within the tumor, which may be bone, cartilage or fibrous tissue, and it is correspondingly referred to as osteoblastic, chondroblastic and fibroblastic osteosarcoma. The remaining 25% of cases have unique parameters that allow reproducible identification of tumors which are biologically different from conventional osteosarcoma and are referred to as "Variants." The parameters identifying Variants fall into one of three major groups: (1) clinical factors, (2) histologic findings and (3) location of origin--within or on the cortex. Because of their inherent biological difference from Conventional Osteosarcoma, the Variants identify cases which must be excluded from analysis of data pertaining to the treatment of the majority of cases: Conventional Osteosarcoma. The diagnostic parameters of osteosarcoma must be sufficiently inclusive to identify all the members of this potentially lethal tumor. Conversely, criteria for sub classification must be restricted to assure homogenous populations of tumors productively incorporating different biological behavior and the potential for development of unique treatment strategies which are different from those for Conventional Osteosarcoma. This can be designated "Classification Based Therapy" or "Therapy Based Osteosarcoma." With this background, we will discuss the highly disciplined approach to the management of osteosarcoma from the pathologist's perspective. Factors governing the assessment of the response to preoperative chemotherapy will also be reviewed.

Entities:  

Mesh:

Year:  2009        PMID: 20213386     DOI: 10.1007/978-1-4419-0284-9_4

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  35 in total

1.  Ankylosing spondylitis and the risk of cancer.

Authors:  Chih-Cheng Chang; Cheng-Wei Chang; Phung-Anh Alex Nguyen; Tzu-Hao Chang; Ya-Ling Shih; Wen-Ying Chang; Jorng-Tzong Horng; Oscar Kuang-Sheng Lee; Jennifer Hui-Chun Ho
Journal:  Oncol Lett       Date:  2017-06-09       Impact factor: 2.967

2.  Baicalein suppresses the viability of MG-63 osteosarcoma cells through inhibiting c-MYC expression via Wnt signaling pathway.

Authors:  Nengbin He; Zhichang Zhang
Journal:  Mol Cell Biochem       Date:  2015-04-18       Impact factor: 3.396

3.  Estrogen-related receptor α participates transforming growth factor-β (TGF-β) induced epithelial-mesenchymal transition of osteosarcoma cells.

Authors:  Yantao Chen; Kunshui Zhang; Yang Li; Qing He
Journal:  Cell Adh Migr       Date:  2016-08-17       Impact factor: 3.405

4.  Clinico-pathological Study of Limb Salvage Surgery for Osteosarcoma: Experience in a Rural Cancer Center.

Authors:  Divya Vijayanarasimha; Sangeetha K Nayanar; Syam Vikram; Vijay M Patil; Satheesh Babu
Journal:  Indian J Surg Oncol       Date:  2016-08-30

5.  Positron Emission Tomography Detects In Vivo Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma.

Authors:  Elizabeth R Butch; Paul E Mead; Victor Amador Diaz; Heather Tillman; Elizabeth Stewart; Jitendra K Mishra; Jieun Kim; Armita Bahrami; Jason L J Dearling; Alan B Packard; Shana V Stoddard; Amy L Vāvere; Yuanyuan Han; Barry L Shulkin; Scott E Snyder
Journal:  Cancer Res       Date:  2019-04-23       Impact factor: 12.701

6.  Diosgenin exerts its tumor suppressive function via inhibition of Cdc20 in osteosarcoma cells.

Authors:  Cheng Long; Juan Chen; Hua Zhou; Tao Jiang; Xiang Fang; Dong Hou; Ping Liu; Hong Duan
Journal:  Cell Cycle       Date:  2019-01-22       Impact factor: 4.534

7.  Initial diagnostic management of pediatric bone tumors.

Authors:  Rodrigo B Interiano; Alpin D Malkan; Amos H P Loh; Nathan Hinkle; Fazal N Wahid; Armita Bahrami; Shenghua Mao; Jianrong Wu; Michael W Bishop; Michael D Neel; Robert E Gold; Bhaskar N Rao; Andrew M Davidoff; Israel Fernandez-Pineda
Journal:  J Pediatr Surg       Date:  2016-03-02       Impact factor: 2.545

Review 8.  Osteosarcoma: a review of current and future therapeutic approaches.

Authors:  Xin Zhao; Qirui Wu; Xiuqing Gong; Jinfeng Liu; Yujie Ma
Journal:  Biomed Eng Online       Date:  2021-03-02       Impact factor: 2.819

9.  KLF8 knockdown suppresses proliferation and invasion in human osteosarcoma cells.

Authors:  Feng Lin; Zan Shen; Li-Na Tang; Shui-Er Zheng; Yuan-Jue Sun; Da-Liu Min; Yang Yao
Journal:  Mol Med Rep       Date:  2014-03-07       Impact factor: 2.952

10.  Cross Talk Between Autophagy and Apoptosis Contributes to ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death.

Authors:  Guanping He; Yunlong Ma; Ye Zhu; Lei Yong; Xiao Liu; Peng Wang; Chen Liang; Chenlong Yang; Zhigang Zhao; Bao Hai; Xiaoyu Pan; Zhongjun Liu; Xiaoguang Liu; Chuanbin Mao
Journal:  Adv Healthc Mater       Date:  2018-06-14       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.